Literature DB >> 17662474

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Roger Paredes1, Vincent C Marconi, Thomas B Campbell, Daniel R Kuritzkes.   

Abstract

Allele-specific PCR (ASPCR) is a highly sensitive, and reproducible method for the study of minor HIV-1 variants harboring resistance mutations and is significantly less labor-intensive and time-consuming than other techniques used for similar purposes. Furthermore, ASPCR has multiple applications in HIV research: it provides earlier and more sensitive detection of evolving resistance mutations, a more accurate assessment of transmitted drug-resistant mutants and a better evaluation of resistance selection after post-exposure or mother-to-child-transmission prophylaxis programs. This article outlines the principles of ASPCR and illustrates technical challenges in the design and application of ASPCR protocols by describing ASPCR assays developed for detecting resistance mutations in the protease (PR)- and reverse transcriptase (RT)-coding regions of pol and env. The assays achieved sensitivities of <1% for the D30N mutation in HIV-1 PR, M184V and I mutations in RT, and V38A in gp41. This method can be easily adapted to the quantitative detection of other mutations in HIV-1 or other viruses by introducing minor modifications to the methods described. In addition, ASPCR can be used to assess the dynamics of mutant populations in the viral quasispecies in response to changing selection pressures, allowing inferences on viral fitness in vivo through mathematical modeling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662474      PMCID: PMC4195598          DOI: 10.1016/j.jviromet.2007.06.012

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  37 in total

1.  Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

Authors:  L Ross; Q Liao; H Gao; S Pham; J Tolson; K Hertogs; B Larder; M S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2001-10-10       Impact factor: 2.205

2.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

3.  Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.

Authors:  Elias K Halvas; Grace M Aldrovandi; Peter Balfe; Ingrid A Beck; Valerie F Boltz; John M Coffin; Lisa M Frenkel; J Darren Hazelwood; Victoria A Johnson; Mary Kearney; Andrea Kovacs; Daniel R Kuritzkes; Karin J Metzner; Dwight V Nissley; Marek Nowicki; Sarah Palmer; Rainer Ziermann; Richard Y Zhao; Cheryl L Jennings; James Bremer; Don Brambilla; John W Mellors
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

5.  Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe.

Authors:  Claudia González-López; Gema Gómez-Mariano; Cristina Escarmís; Esteban Domingo
Journal:  Infect Genet Evol       Date:  2005-10       Impact factor: 3.342

6.  Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

Authors:  T Middleton; D Smith; B Larder; M Law; C Birch
Journal:  HIV Clin Trials       Date:  2001 Nov-Dec

7.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

8.  Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.

Authors:  Shayne Loubser; Peter Balfe; Gayle Sherman; Scott Hammer; Louise Kuhn; Lynn Morris
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

9.  Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR.

Authors:  Tobias Bergroth; Anders Sönnerborg; Zhibing Yun
Journal:  J Virol Methods       Date:  2005-04-18       Impact factor: 2.014

10.  HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Authors:  C A Boucher; J M Lange; F F Miedema; G J Weverling; M Koot; J W Mulder; J Goudsmit; P Kellam; B A Larder; M Tersmette
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

View more
  27 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.

Authors:  Christopher F Rowley; Christian L Boutwell; Shahin Lockman; M Essex
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

5.  Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes.

Authors:  David Sacks; Johanna Ledwaba; Lynn Morris; Gillian M Hunt
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

Review 6.  The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Authors:  Natalia Stella-Ascariz; José Ramón Arribas; Roger Paredes; Jonathan Z Li
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

7.  Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.

Authors:  Matthew McCallum; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Victor G Kramer; Daniela Moisi; Eugene L Asahchop; Bluma G Brenner; P Richard Harrigan; Hongtao Xu; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

8.  Clinical implications of HIV-1 minority variants.

Authors:  Jonathan Z Li; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2013-02-27       Impact factor: 9.079

9.  Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.

Authors:  Andrea Hauser; Kizito Mugenyi; Rose Kabasinguzi; Kerstin Bluethgen; Claudia Kuecherer; Gundel Harms; Andrea Kunz
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

10.  In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Authors:  Roger Paredes; Manish Sagar; Vincent C Marconi; Rebecca Hoh; Jeffrey N Martin; Neil T Parkin; Christos J Petropoulos; Steven G Deeks; Daniel R Kuritzkes
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.